A Phase 2 interventional study of Intranasal Placebo and Midazolam Placebo Solution in Depressive Disorder, Major, sponsored by Janssen Research & Development, LLC. Completed at 51 sites in 9 countries. Open to participants aged 9 Years to 17 Years. Per ClinicalTrials.gov, last updated 2025-04-29.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing esketamine in Depressive Disorder, Major — 5 open to participants now, 5 under way, 2 of them phase 3. Esketamine · Depressive Disorder, Major.
Among the 17 studies testing esketamine in Depressive Disorder, Major, this one is the 9th largest by enrollment, is one of 3 that started in 2017, is one of 3 in phase 2, and was the 6th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →5 of the 17 studies testing esketamine in Depressive Disorder, Major are open now, in 12 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States, Brazil, Hungary and 4 more countries
Ages 12–17
Dr. Inge Winter · Sites in Austria, Germany, Greece and 3 more countries
Ages 18–65
Royal North Shore Hospital · Sites in Australia
Ages 18–65
Massachusetts General Hospital · Sites in United States
Ages 18–70
Medical University of Vienna · Sites in Austria
Ages 18–55 · Healthy volunteers
By country, each count listing its studies:
Esketamine: first FDA approval 2019 (SPRAVATO), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 9 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 147 is above the median of 79 across 2,533 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 147 across the 17 interventional studies. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 17 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
59 studies in Depressive Disorder, Major by Johnson & Johnson: 5 open now, 5 under way, 5 of them phase 3. Of 53 finished, 26 (49%) have results posted.
Among the 59 studies in Depressive Disorder, Major by Johnson & Johnson, this one is the 31st largest by enrollment of the 52 interventional ones that give a count, is one of 5 that started in 2017, is one of 17 in phase 2, and was the 27th registered.
Johnson & Johnson’s Depressive Disorder, Major studies by the year they started, since 2002.
1 of the studies testing esketamine in Depressive Disorder, Major that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05450432Massachusetts General HospitalLong-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression | 2027-05-01 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies testing esketamine in Depressive Disorder, Major, from their registry updates:
Among Johnson & Johnson’s 59 in Depressive Disorder, Major:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy of a single (first) dose of 3 fixed doses of intranasal esketamine {28 milligram (mg), 56 mg, and 84 mg} compared with psychoactive placebo (oral midazolam) in rapidly reducing the symptoms of major depressive disorder (MDD) including suicidal ideation in participants 12 to less than 18 years of age who are assessed to be at imminent risk for suicide.
This study will enroll participants with major depressive disorder (MDD) presenting with suicidal ideation who are assessed to be at imminent risk for suicide. The study will be conducted in 4 phases: a screening evaluation performed within 48 hours prior to Day 1 intranasal dose; a 25-day double-blind treatment phase (Days 1-25); an 8-week initial post-treatment phase (Days 25-81); and a subsequent phase to complete a full 6-month post-treatment follow-up (Days 81-200). Efficacy, safety, pharmacokinetic, biomarker, and pharmacogenomic evaluations will be performed in the study at defined schedule. The duration of the participant's participation will be approximately 29 weeks. If you or a loved one are having thoughts of suicide, please seek immediate medical help. Go to the emergency room or call the National Suicide Prevention Lifeline at 1-800-273-8255.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive midazolam solution 0.125 milligram per kilogram (mg/kg) orally 2 times per week for 4 weeks and 3 intranasal doses of matched placebo to esketamine.
Drug: Intranasal Placebo · Drug: Midazolam
Participants will receive intranasal esketamine 84 mg as 3 intranasal doses of esketamine in each nostril (each dose contains 14 mg of esketamine) along with oral placebo 2 times per week for 4 weeks.
Drug: Midazolam Placebo Solution · Drug: Esketamine
Participants will receive intranasal esketamine 56 mg as 2 intranasal doses of esketamine in each nostril (each dose contains 14 mg of esketamine) along with oral placebo 2 times per week for 4 weeks.
Drug: Midazolam Placebo Solution · Drug: Esketamine
Participants will receive intranasal esketamine 28 mg as 1 intranasal doses of esketamine in each nostril (each dose contains 14 mg of esketamine) along with oral placebo 2 times per week for 4 weeks.
Drug: Midazolam Placebo Solution · Drug: Esketamine
Participants will receive placebo as intranasal dose to match intranasal esketamine.
Participants will receive placebo as oral dose to match midazolam drug.
Participants will receive midazolam solution 0.125 mg/kg as oral dose to match placebo.
Participants will receive esketamine at a dose of 28 mg as intranasal solution.
Participants will receive esketamine at a dose of 56 mg as intranasal solution.
Participants will receive esketamine at a dose of 84 mg as intranasal solution.
Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at 24 Hours Post First Dose (Day 2)
The CDRS-R is a validated 17- item, clinician-rated instrument developed to assess depressive symptomatology in children. Scores were based on interviews with both the child and their caregiver. Of the 17-item, 3 items were non-verbal behavior (listless speech, hypoactivity, and depressed affect) rated on a 5-point scale from 1 (no depression) to 5 (severe depression) and 14 items were rated on a 7-point scale from 1 (no depression) to 7 (severe depression), where higher score indicated more severe depression. The CDRS-R total score was the sum of the 17-tems score and it ranged from 17 (normal) to 113 (severe depression). Higher score indicated more severe depression and worse outcome.
Time frame: Baseline (predose on Day 1) and 24 hours post first dose on Day 1 (i.e., Day 2)
A total of 147 participants were randomized and treated. One participant (randomized to arm "Esketamine 84 mg+Placebo+standard of care \[SOC\]") was excluded from the efficacy analysis set, safety analysis set, and follow-up analysis set due to Good Clinical Practice (GCP) issue at the site.
| Milestone | Placebo + Midazolam + SOC | Esketamine 28 mg + Placebo + SOC | Esketamine 56 mg + Placebo + SOC | Esketamine 84 mg + Placebo + SOC |
|---|---|---|---|---|
| Started | 63 | 29 | 31 | 24 |
| Safety analysis set | 63 | 29 | 31 | 23 |
| Full efficacy analysis set | 63 | 28 | 31 | 23 |
| Follow-up analysis set | 59 | 29 | 29 | 21 |
| Completed | 59 | 29 | 29 | 22 |
| Not completed | 4 | 0 | 2 | 2 |
| Withdrew: Withdrawal by parent/guardian | 0 | 0 | 0 | 1 |
| Withdrew: Other | 1 | 0 | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 2 | 0 | 1 | 0 |
| Withdrew: Subject refused further study treatment | 0 | 0 | 0 | 1 |
| Milestone | Placebo + Midazolam + SOC | Esketamine 28 mg + Placebo + SOC | Esketamine 56 mg + Placebo + SOC | Esketamine 84 mg + Placebo + SOC |
|---|---|---|---|---|
| Started | 59 | 29 | 29 | 21 |
| Completed | 48 | 24 | 21 | 18 |
| Not completed | 11 | 5 | 8 | 3 |
| Withdrew: Withdrawal by parent/guardian | 1 | 0 | 1 | 0 |
| Withdrew: Other | 1 | 0 | 3 | 1 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 |
| Withdrew: Requires treatment with electroconvulsive therapy, transcranial magnetic stimulation, ketamine | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 3 | 2 | 0 |
| Withdrew: Physician decision | 2 | 0 | 2 | 0 |
| Withdrew: Lost to follow-up | 2 | 1 | 0 | 2 |
| Withdrew: Death | 1 | 0 | 0 | 0 |
The CDRS-R is a validated 17- item, clinician-rated instrument developed to assess depressive symptomatology in children. Scores were based on interviews with both the child and their caregiver. Of the 17-item, 3 items were non-verbal behavior (listless speech, hypoactivity, and depressed affect) rated on a 5-point scale from 1 (no depression) to 5 (severe depression) and 14 items were rated on a 7-point scale from 1 (no depression) to 7 (severe depression), where higher score indicated more severe depression. The CDRS-R total score was the sum of the 17-tems score and it ranged from 17 (normal) to 113 (severe depression). Higher score indicated more severe depression and worse outcome.
| Units on a scale | Placebo + Midazolam + SOC | Esketamine 28 mg + Placebo + SOC | Esketamine 56 mg + Placebo + SOC | Esketamine 84 mg + Placebo + SOC | Pooled Esketamine 56 mg + Esketamine 84 mg |
|---|---|---|---|---|---|
| Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at 24 Hours Post First Dose (Day 2) | -26.2 ± 16.72 | -29.6 ± 18.15 | -31.8 ± 12.92 | -30.3 ± 17.48 | -31.2 ± 14.90 |
Collected over Double Blind treatment phase: From Day 1 to Day 25; Follow-up phase: From Day 26 up to end of post-treatment follow-up phase (Day 200). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DB: Placebo + Midazolam + SOC | 0/63 (0%) | 9/63 (14.3%) | 57/63 (90.5%) |
| DB: Esketamine 28 mg + Placebo + SOC | 0/29 (0%) | 4/29 (13.8%) | 26/29 (89.7%) |
| DB: Esketamine 56 mg + Placebo + SOC | 0/31 (0%) | 7/31 (22.6%) | 30/31 (96.8%) |
| DB: Esketamine 84 mg + Placebo + SOC | 0/23 (0%) | 1/23 (4.3%) | 23/23 (100%) |
| FU Phase: Placebo + Midazolam + SOC | 1/59 (1.7%) | 19/59 (32.2%) | 48/59 (81.4%) |
| FU Phase: Esketamine 28 mg + Placebo + SOC | 0/29 (0%) | 10/29 (34.5%) | 21/29 (72.4%) |
| FU Phase: Esketamine 56 mg + Placebo + SOC | 0/29 (0%) | 8/29 (27.6%) | 19/29 (65.5%) |
| FU Phase: Esketamine 84 mg + Placebo + SOC | 0/21 (0%) | 7/21 (33.3%) | 14/21 (66.7%) |
| Event | DB: Placebo + Midazolam + SOC | DB: Esketamine 28 mg + Placebo + SOC | DB: Esketamine 56 mg + Placebo + SOC | DB: Esketamine 84 mg + Placebo + SOC | FU Phase: Placebo + Midazolam + SOC | FU Phase: Esketamine 28 mg + Placebo + SOC | FU Phase: Esketamine 56 mg + Placebo + SOC | FU Phase: Esketamine 84 mg + Placebo + SOC |
|---|---|---|---|---|---|---|---|---|
| Suicide AttemptPsychiatric disorders | 5/63 | 1/29 | 5/31 | 1/23 | 9/59 | 3/29 | 5/29 | 4/21 |
| Suicidal IdeationPsychiatric disorders | 3/63 | 3/29 | 2/31 | 0/23 | 4/59 | 5/29 | 3/29 | 3/21 |
| Depression SuicidalPsychiatric disorders | 1/63 | 1/29 | 0/31 | 0/23 | 3/59 | 2/29 | 1/29 | 1/21 |
| Intentional Self-InjuryPsychiatric disorders | 0/63 | 0/29 | 0/31 | 0/23 | 2/59 | 2/29 | 0/29 | 1/21 |
| Alcohol PoisoningInjury, poisoning and procedural complications | 0/63 | 0/29 | 0/31 | 0/23 | 0/59 | 0/29 | 0/29 | 1/21 |
| Humerus FractureInjury, poisoning and procedural complications | 0/63 | 0/29 | 0/31 | 0/23 | 0/59 | 0/29 | 0/29 | 1/21 |
| Intentional OverdoseInjury, poisoning and procedural complications | 0/63 | 0/29 | 0/31 | 0/23 | 0/59 | 0/29 | 0/29 | 1/21 |
| Pelvic FractureInjury, poisoning and procedural complications | 0/63 | 0/29 | 0/31 | 0/23 | 0/59 | 0/29 | 0/29 | 1/21 |
| Food RefusalMetabolism and nutrition disorders | 0/63 | 0/29 | 0/31 | 0/23 | 0/59 | 0/29 | 0/29 | 1/21 |
| Status MigrainosusNervous system disorders | 0/63 | 0/29 | 0/31 | 0/23 | 0/59 | 0/29 | 0/29 | 1/21 |
| Event | DB: Placebo + Midazolam + SOC | DB: Esketamine 28 mg + Placebo + SOC | DB: Esketamine 56 mg + Placebo + SOC | DB: Esketamine 84 mg + Placebo + SOC | FU Phase: Placebo + Midazolam + SOC | FU Phase: Esketamine 28 mg + Placebo + SOC | FU Phase: Esketamine 56 mg + Placebo + SOC | FU Phase: Esketamine 84 mg + Placebo + SOC |
|---|---|---|---|---|---|---|---|---|
| DizzinessNervous system disorders | 27/63 | 16/29 | 16/31 | 16/23 | 3/59 | 0/29 | 2/29 | 0/21 |
| NauseaGastrointestinal disorders | 11/63 | 8/29 | 15/31 | 13/23 | 9/59 | 3/29 | 3/29 | 1/21 |
| DissociationPsychiatric disorders | 11/63 | 12/29 | 12/31 | 11/23 | 1/59 | 1/29 | 1/29 | 0/21 |
| HeadacheNervous system disorders | 18/63 | 10/29 | 13/31 | 7/23 | 12/59 | 10/29 | 7/29 | 3/21 |
| DysgeusiaNervous system disorders | 15/63 | 10/29 | 8/31 | 9/23 | 0/59 | 0/29 | 0/29 | 0/21 |
| SomnolenceNervous system disorders | 24/63 | 10/29 | 9/31 | 8/23 | 2/59 | 0/29 | 1/29 | 0/21 |
| Intentional Self-InjuryPsychiatric disorders | 12/63 | 6/29 | 6/31 | 5/23 | 21/59 | 7/29 | 3/29 | 7/21 |
| VomitingGastrointestinal disorders | 4/63 | 5/29 | 7/31 | 6/23 | 4/59 | 3/29 | 0/29 | 0/21 |
| HypoaesthesiaNervous system disorders | 2/63 | 5/29 | 8/31 | 4/23 | 0/59 | 0/29 | 0/29 | 0/21 |
| Hypoaesthesia OralGastrointestinal disorders | 0/63 | 6/29 | 6/31 | 5/23 | 1/59 | 0/29 | 0/29 | 0/21 |
All baseline characteristics were analyzed on the safety analysis set which included all randomized participants who received at least one dose of DB study drug.
| Age, Continuous(years) | Placebo + Midazolam + SOC | Esketamine 28 mg + Placebo + SOC | Esketamine 56 mg + Placebo + SOC | Esketamine 84 mg + Placebo + SOC | Total |
|---|---|---|---|---|---|
| Mean | 15.2 ± 1.45 | 14.9 ± 1.33 | 14.8 ± 1.52 | 14.3 ± 1.43 | 14.9 ± 1.46 |
| Age, Customized(Participants) | Placebo + Midazolam + SOC | Esketamine 28 mg + Placebo + SOC | Esketamine 56 mg + Placebo + SOC | Esketamine 84 mg + Placebo + SOC | Total |
|---|---|---|---|---|---|
| Children (2-11 years) | 0 | 0 | 0 | 0 | 0 |
| Adolescents (12-17 years) | 63 | 29 | 31 | 23 | 146 |
| Adults (18-64 years) | 0 | 0 | 0 | 0 | 0 |
| From 65 to 84 years | 0 | 0 | 0 | 0 | 0 |
| 85 years and over | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Placebo + Midazolam + SOC | Esketamine 28 mg + Placebo + SOC | Esketamine 56 mg + Placebo + SOC | Esketamine 84 mg + Placebo + SOC | Total |
|---|---|---|---|---|---|
| Female | 48 | 24 | 25 | 17 | 114 |
| Male | 15 | 5 | 6 | 6 | 32 |
| Ethnicity (NIH/OMB)(Participants) | Placebo + Midazolam + SOC | Esketamine 28 mg + Placebo + SOC | Esketamine 56 mg + Placebo + SOC | Esketamine 84 mg + Placebo + SOC | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 16 | 7 | 8 | 3 | 34 |
| Not Hispanic or Latino | 46 | 19 | 20 | 19 | 104 |
| Unknown or Not Reported | 1 | 3 | 3 | 1 | 8 |
| Race (NIH/OMB)(Participants) | Placebo + Midazolam + SOC | Esketamine 28 mg + Placebo + SOC | Esketamine 56 mg + Placebo + SOC | Esketamine 84 mg + Placebo + SOC | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 0 | 0 | 0 | 2 |
| Asian | 1 | 0 | 2 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 6 | 4 | 1 | 4 | 15 |
| White | 53 | 25 | 23 | 17 | 118 |
| More than one race | 0 | 0 | 2 | 0 | 2 |
| Unknown or Not Reported | 1 | 0 | 3 | 2 | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2017 to primary completion in Mar 2023, 65 months.
Results were first posted in Apr 2024, 1 year after primary completion.
Of 96 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's 65 months is above that.
Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Esketamine
Janssen Research & Development, LLC →